Compare SBET & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | ARDX |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2025 | 2014 |
| Metric | SBET | ARDX |
|---|---|---|
| Price | $6.80 | $6.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $18.71 | $15.14 |
| AVG Volume (30 Days) | ★ 6.9M | 4.2M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | $2,607,000.00 |
| Revenue This Year | $105.19 | $37.75 |
| Revenue Next Year | $13.53 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $2.58 | $3.54 |
| 52 Week High | $124.12 | $8.40 |
| Indicator | SBET | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 45.83 |
| Support Level | $6.05 | $5.54 |
| Resistance Level | $8.26 | $6.44 |
| Average True Range (ATR) | 0.39 | 0.36 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 5.68 | 27.02 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.